STOCK TITAN
  1. Home
  2. Sec-filings
  3. CYTK
  4. [Form 4] CYTOKINETICS INC Insider Trading Activity

Cytokinetics CEO reports sale of 5,000 shares (Form 4)

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Cytokinetics (CYTK) disclosed an insider transaction via Form 4. President & CEO and Director Mr. Blum reported a sale of 5,000 shares of common stock on 10/30/2025 at a price of $62.86 per share (transaction code S). Following the sale, he beneficially owns 358,108 shares directly.

He also reports indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. No derivative securities were reported in this filing.

Positive

  • None.

Negative

  • None.
Insider Blum Robert I
Role President & CEO
Sold 5,000 shs ($314K)
Type Security Shares Price Value
Sale Common Stock 5,000 $62.86 $314K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 358,108 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1)
Footnotes (1)
  1. Shares held by The Bridget Blum 2003 Irrevocable Trust. Shares held by The Brittany Blum 2003 Irrevocable Trust.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blum Robert I
(Last) (First) (Middle)
350 OYSTER POINT BLVD
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/30/2025 S 5,000 D $62.86 358,108 D
Common Stock 2,083 I by Trust 1(1)
Common Stock 2,083 I by Trust 2(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
/s/ John O. Faurescu, attorney-in-fact for Mr. Blum 10/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction was reported for CYTK?

Mr. Blum reported a sale of 5,000 shares of Cytokinetics common stock on 10/30/2025 at $62.86 per share (code S).

Who is the reporting person in the CYTK Form 4?

Mr. Blum, who serves as President & CEO and Director of Cytokinetics.

How many CYTK shares does the insider hold after the transaction?

He beneficially owns 358,108 shares directly after the reported sale.

What indirect CYTK holdings were disclosed?

Indirect holdings include 2,083 shares in The Bridget Blum 2003 Irrevocable Trust and 2,083 shares in The Brittany Blum 2003 Irrevocable Trust.

Were any derivative securities reported in this CYTK Form 4?

No. No derivative securities were listed in the filing.

What was the transaction code in the CYTK Form 4?

The filing lists transaction code S, indicating an open market or private sale of non-derivative securities.